US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 23:49:30 Source:sportViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Arrest Lord Mountbatten's self
Next:Insider Q&A: CIA's chief technologist's cautious embrace of generative AI
You may also like
- Strictly star Nadiya Bychkova reveals she doesn't know if she's on the show's 2024 line
- NASCAR All
- Death toll from south Brazil's climate disaster hits 151
- China, Azerbaijan vow to lift bilateral relations to new heights
- Travis Kelce downs whiskey shot on slice of bread at Kelce Jam without Taylor Swift
- Jodie Turner
- Parents of disabled children sue Indiana over Medicaid changes addressing $1 billion shortfall
- Michigan lawmakers get final revenue estimates as they push to finalize the state budget
- Nadal returns to Roland Garros to practice amid doubts over fitness and form